Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study

NCT02729766 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Inappropriate ADH Syndrome

Interventions

OTHER: Induced hypotonic hyponatremia - SIAD model
DRUG: Empagliflozin 25mg Tbl
DRUG: Placebo P-Tablet

Sponsor

University Hospital, Basel, Switzerland